| 000 | 01891 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518003821.0 | ||
| 264 | 0 | _c20190502 | |
| 008 | 201905s 0 0 eng d | ||
| 022 | _a1744-8379 | ||
| 024 | 7 |
_a10.1080/14737167.2019.1537784 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRuggeri, M | |
| 245 | 0 | 0 |
_aCost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy. _h[electronic resource] |
| 260 |
_bExpert review of pharmacoeconomics & outcomes research _cJun 2019 |
||
| 300 |
_a363-374 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBenzimidazoles _xadministration & dosage |
| 650 | 0 | 4 | _aCarbamates |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aFluorenes _xadministration & dosage |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xadministration & dosage |
| 650 | 0 | 4 | _aItaly |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 | _aPyrrolidines |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 |
_aRibavirin _xadministration & dosage |
| 650 | 0 | 4 |
_aSimeprevir _xadministration & dosage |
| 650 | 0 | 4 |
_aSofosbuvir _xadministration & dosage |
| 650 | 0 | 4 |
_aUridine Monophosphate _xadministration & dosage |
| 650 | 0 | 4 |
_aValine _xanalogs & derivatives |
| 700 | 1 | _aRolli, F R | |
| 700 | 1 | _aKondili, L A | |
| 700 | 1 | _aDrago, C | |
| 700 | 1 | _aDe Solda, F | |
| 700 | 1 | _aNappi, C | |
| 700 | 1 | _aCicchetti, A | |
| 773 | 0 |
_tExpert review of pharmacoeconomics & outcomes research _gvol. 19 _gno. 3 _gp. 363-374 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/14737167.2019.1537784 _zAvailable from publisher's website |
| 999 |
_c28969428 _d28969428 |
||